Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS Q61L||melanoma||sensitive||CCT241161||Preclinical - Cell line xenograft||Actionable||In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).||25500121 23431193|
|PubMed Id||Reference Title||Details|
|(25500121)||Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.||Full reference...|
|(23431193)||Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.||Full reference...|